SCHEMBL1759451

SCHEMBL1759451

N#Cc1ccccc1CF

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP19A1 P11511 1/20 0.46
SMN1; SMN2 Q16637 3/20 0.44
ALDH1A1 P00352 2/20 0.44
TSHR P16473 2/20 0.44
MAPT P10636 1/20 0.44
KDM4E B2RXH2 1/20 0.38
HPGD P15428 1/20 0.38
HSD17B10 Q99714 1/20 0.38
SLC6A2 P23975 1/20 0.38
SLC6A4 P31645 1/20 0.38
CYP1A1 P04798 1/20 0.38
CYP1A2 P05177 1/20 0.38
CYP1B1 Q16678 1/20 0.38
FFAR1 O14842 1/20 0.37
CA1 P00915 1/20 0.36
CA2 P00918 1/20 0.36
USP8 P40818 1/20 0.36
USP7 Q93009 1/20 0.36
NPC1 O15118 1/20 0.36
RAB9A P51151 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2154210 0.80 SMN1; SMN2 (0.49) CYP19A1SMN1; SMN2ALDH1A1TSHRMAPT
SCHEMBL2153612 0.80 CYP19A1 (0.48) CYP19A1SMN1; SMN2ALDH1A1TSHRMAPT
SCHEMBL15898401 0.79 TSHR (0.43) CYP19A1SMN1; SMN2ALDH1A1TSHRMAPT
SCHEMBL10911676 0.78 GABRA1 (0.30) CYP1A1CYP1A2CYP1B1
SCHEMBL19356915 0.78 CYP19A1 (0.47) CYP19A1SMN1; SMN2ALDH1A1TSHRMAPT
SCHEMBL899 0.76 CYP19A1 (0.46) CYP19A1SMN1; SMN2ALDH1A1TSHRMAPT
Bromide SCHEMBL1841105 0.76 CYP19A1 (0.46) CYP19A1SMN1; SMN2ALDH1A1TSHRMAPT
SCHEMBL5327089 0.76 CYP19A1 (0.46) CYP19A1SMN1; SMN2ALDH1A1TSHRMAPT
SCHEMBL1110228 0.76 CYP19A1 (0.46) CYP19A1SMN1; SMN2ALDH1A1TSHRMAPT
SCHEMBL840560 0.76 CYP19A1 (0.46) CYP19A1SMN1; SMN2ALDH1A1TSHRMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2015092739-A1 PROCESS FOR PREPARATION OF ALOGLIPTIN Mylan Laboratories Ltd. (IN) 2015-06-25 WO claimed
EP-1670446-A2 METHOD OF INHIBITING REMNANT LIPOPROTEIN PRODUCTION JAPAN TOBACCO INC. (JP) 2006-06-21 EP claimed
WO-2005030185-A2 METHOD OF INHIBITING REMNANT LIPOPROTEIN PRODUCTION JAPAN TOBACCO INC. (JP) 2005-04-07 WO claimed
CN-1221407-A Aminoisoquinolines and aminothienopyridine derivatives and their use as anti-inflammatory agents ASTRA PHARMA PROD (GB) 1999-06-30 CN claimed
CN-110337433-A Compounds and pharmaceutical compositions for modulating SGK activity and methods thereof 新时代医药科技南京有限公司 2019-10-15 CN disclosed
CN-109715615-A Biaryl methyl heterocycles 蒙特利尔大学 2019-05-03 CN disclosed
CN-105209444-A Benzo-fused heterocyclic derivatives useful as agonists of GPR120 JANSSEN PHARMACEUTICA NV 2015-12-30 CN disclosed
WO-2015092739-A1 PROCESS FOR PREPARATION OF ALOGLIPTIN Mylan Laboratories Ltd. (IN) 2015-06-25 WO disclosed
CN-101970420-B Oxadiazole derivatives MERCK SERONO SA 2014-09-24 CN disclosed
CN-101573351-B Polymorphs of succinate salt of 2-[6-(3-amino-piperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2h-pyrimidin-1-ylmethy]-4-fluor-benzonitrile and methods of use therefor TAKEDA PHARMACEUTICAL 2014-06-18 CN disclosed
CN-103874493-A Inhibitors of the renal outer medullary potassium channel MERCK SHARP & DOHME 2014-06-18 CN disclosed
WO-2014087165-A1 TANKYRASE INHIBITORS UNIVERSITY OF BATH (GB) 2014-06-12 WO disclosed
WO-2011057956-A1 BENZISOXAZOLE ANALOGS AS GLYCOGEN SYNTHASE ACTIVATORS F. HOFFMANN-LA ROCHE AG (CH) 2011-05-19 WO disclosed
US-20110112158-A1 BENZISOXAZOLE ANALOGS AS GLYCOGEN SYNTHASE ACTIVATORS BOLIN DAVID ROBERT 2011-05-12 US disclosed
CN-101815707-A oxadiazole diaryl compounds MERCK SERONO SA 2010-08-25 CN disclosed
US-7696238-B2 Substituted benzo[d]isoxazol-3-yl amine compounds as analgesics GRUENENTHAL GMBH (DE) 2010-04-13 US disclosed
CN-101573351-A Polymorphs of succinate salt of 2-[6-(3-amino-piperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2h-pyrimidin-1-ylmethy]-4-fluor-benzonitrile and methods of use therefor TAKEDA PHARMACEUTICAL (JP) 2009-11-04 CN disclosed
EP-1465880-B1 5-SULPHANYL-4H-1,2,4-TRIAZOLE DERIVATIVES AND THEIR USE TO TREAT DISORDERS ASSOCIATED WITH SOMATOSTATINE IPSEN PHARMA (FR) 2009-08-05 EP disclosed
US-20040006230-A1 Useful as inhibitors of serine proteases; for therapy and prophylaxis of thrombotic conditions including coronary artery and cerebrovascular diseases PHARMACIA CORPORATION 2004-01-08 US disclosed
CN-1221407-A Aminoisoquinolines and aminothienopyridine derivatives and their use as anti-inflammatory agents ASTRA PHARMA PROD (GB) 1999-06-30 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110112158-A1 BENZISOXAZOLE ANALOGS AS GLYCOGEN SYNTHASE ACTIVATORS GYS2, GYS1, PYGL CYP19A1 130/4885SMN1; SMN2 1624/4885ALDH1A1 596/4885
US-20040006230-A1 Useful as inhibitors of serine proteases; for therapy and prophylaxis of thrombotic conditions including coronary artery and cerebrovascular diseases PRSS1, SERPINC1, SERPINE1 CYP19A1 1650/4885SMN1; SMN2 2680/4885ALDH1A1 3078/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.